TF Capital is an investment firm that focuses on investing in the life sciences industry.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
TF Capital is an investment firm that focuses on investing in the life sciences industry.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2018 | Eccogene | Series A | 14.6M |
9/2021 | CytoLynx Therapeutics | Funding Round | 0 |
12/2019 | EOC Pharma Group | Series C | 71M |
2/2021 | Regor Therapeutics | Series B | 0 |
3/2022 | Yuesai Biotechnology | Seed Round | 0 |
8/2014 | Zai Lab | Series A | 10M |
6/2018 | Alpha Biopharma | Series A | 37M |
1/2019 | Zion Pharma | Series A | 11.9M |
1/2016 | Zai Lab | Series B | 106.2M |
8/2020 | Hanyu Medical | Series D | 0 |
11/2021 | Allorion Therapeutics | Series A | 0 |
12/2020 | SciNeuro | Series A | 100M |
3/2020 | Oceanus Plus | Series A | - |
12/2021 | Hesguard | Seed Round | 15.7M |
12/2014 | CANbridge Pharmaceuticals | Series A | 10M |
12/2018 | BioNova Pharma | Series A | - |
10/2021 | ShouTi | Series B | 0 |
3/2014 | Sanyou Medical | Series A | - |
9/2021 | Cellular Biomedicine Group | Series A | 0 |
2/2017 | Abbisko Therapeutics | Series A | 28M |
4/2016 | Hua Medicine | Series C | 0 |
11/2021 | Positive Sequence Biology | Series A | 0 |
3/2019 | Abbisko Therapeutics | Series B | 42M |
4/2021 | Abogen Biosciences | Series B | 91.6M |
1/2019 | Antengene Corporation | Series B | 0 |
10/2021 | Structure Therapeutics | Series B | 0 |
8/2017 | Antengene Corporation | Series A | 21M |
4/2017 | TongliBio | Private Equity Round | - |
9/2019 | Tisenc | Series B | 11.2M |
12/2016 | Asieris Pharmaceuticals | Series A | - |
3/2015 | Ark Biosciences | Series A | - |
10/2018 | Xgene Pharmaceutical | Series B | 0 |
11/2018 | GenFleet Therapeutics | Series A | 17.3M |
5/2019 | GeneQuantum Healthcare | Series B | 14.8M |
3/2017 | GeneQuantum Healthcare | Series A | 5.8M |
3/2022 | UniXell | Seed Round | 0 |
1/2022 | Chemsemi | Series A | 0 |
5/2022 | AskGene Pharma | Series A | 20M |
1/2015 | Hua Medicine | Series B | 0 |
8/2021 | Etern | Series B | - |
3/2020 | Ranok Therapeutics | Seed Round | 10M |
10/2017 | Xgene Pharmaceutical | Series A | - |
5/2022 | AskGene Pharma | Series A | 0 |
3/2022 | UniXell | Seed Round | 0 |
3/2022 | Yuesai Biotechnology | Seed Round | 0 |
1/2022 | Chemsemi | Series A | 0 |
12/2021 | Hesguard | Seed Round | 0 |
11/2021 | Allorion Therapeutics | Series A | 0 |
11/2021 | Positive Sequence Biology | Series A | 0 |
10/2021 | ShouTi | Series B | 0 |
9/2021 | Cellular Biomedicine Group | Series A | 0 |
9/2021 | CytoLynx Therapeutics | Funding Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|